肾脏分层复合终点在CKD进展试验中的应用:NKF科学工作会议报告
尽管已有获批疗法,许多CKD患者仍出现肾功能进行性丧失,亟需新疗法。肾脏分层复合终点(HCE)通过整合按临床重要性排序的多项结局,有望提升随机对照试验效率。美国国家肾脏基金会(NKF)召开科学工作会议,提出肾脏HCE包括全因死亡、肾衰竭(无论是否启动肾脏替代治疗)、持续GFR下降时间及GFR斜率,认为其是建立疗效的有前景候选,但无终点普适所有情况。
要点
- 肾脏HCE整合全因死亡、肾衰竭、持续GFR下降时间及GFR斜率。
- HCE适合有进展风险但传统终点事件不足的人群。
- 尚无终点普适所有情况,个体GFR斜率差异评估待解决。
核心结论
- 肾脏HCE是建立CKD疗法疗效的有前景候选终点。
- 无终点普适所有情况,需进一步研究HCE应用挑战。
研究设计与样本
- NKF资助的科学工作会议,涉及广泛利益相关方。
主要发现
- 提出肾脏HCE包括全因死亡、肾衰竭(无论是否启动肾脏替代治疗)、持续GFR下降时间及GFR斜率。
关键数值与推荐
- 肾脏HCE包含全因死亡、肾衰竭(无论是否启动肾脏替代治疗)、持续GFR下降时间及GFR斜率。
- 理想人群为有进展风险但试验期间临床事件不足以应用传统时间-事件终点者。
临床怎么用
- 在传统肾脏复合终点试验难以获得足够事件时,可考虑使用肾脏HCE。
- 需根据人群进展风险选择终点,尚无普适方案。
局限性
- 如何最佳评估个体GFR斜率差异等关键挑战尚待进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite approved therapies for chronic kidney disease (CKD), many patients experience progressive loss of kidney function, and there remains an unmet need for additional therapies. Hierarchical composite endpoints (HCEs) have emerged as candidate tools to improve the efficiency of randomized controlled trials (RCTs) by integrating multiple outcomes ranked by clinical importance. The National Kidney Foundation convened a Scientific Workshop involving a broad group of stakeholders to consider the application of HCEs to CKD. A proposed kidney HCE includes all-cause mortality, kidney failure with or without initiation of kidney replacement therapy, time to sustained declines in GFR, and GFR slope. Workshop participants concluded that a kidney HCE is a promising candidate for establishing efficacy of therapies in settings in which we typically conduct large trials that use kidney composite endpoints to establish efficacy. It was acknowledged that no endpoint is universally applicable in all situations. The ideal population for an HCE would be one at risk for progression but unlikely to yield sufficient clinical events during the trial period to permit application of the traditional time-to-event endpoint. Additional investigations are required to address key challenges in application of HCE to CKD, such as how to best assess differences in individual GFR slope.
引用
- Inker LA, Greene T, Chertow GM, et al. Application of a Kidney Hierarchical Composite Endpoints in Trials of CKD Progression: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2026. PMID: 42772350. doi:10.1053/j.ajkd.2026.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。